Abstract: Objective: The objective of this study was to assess if a single 200 mg oral dose (60 mg kavalactones) of a standardised 30% kava (Piper methysticum) extract produced impairments in the ability to construct novel solutions to ambiguous problems, as measured by a computerised version of the Russell Revised Short Form of the Halstead Category Test (RCat).